Assessment of non-tumor liver parenchyma damage in advanced gastric cancer treatment with transarterial infusion chemotherapy: a study using imaging and hepatic injury indicators.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
TAI at our center from July 2015 to July 2023
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Serum markers suggest progression of hepatic fibrosis, consistent with the pathological features of hepatic sinusoidal obstruction syndrome. The combination of CT imaging and APRI/FIB-4 provides a sensitive method for detecting subclinical liver injury, reflecting pathological changes earlier than traditional liver function scores.
[INTRODUCTION] This study aimed to evaluate non-tumor liver parenchymal injury in advanced gastric cancer patients undergoing transarterial infusion chemotherapy (TAI) using imaging parameters and liv
- p-value P < 0.01
APA
Jing Y, Jing J, et al. (2025). Assessment of non-tumor liver parenchyma damage in advanced gastric cancer treatment with transarterial infusion chemotherapy: a study using imaging and hepatic injury indicators.. Frontiers in oncology, 15, 1537688. https://doi.org/10.3389/fonc.2025.1537688
MLA
Jing Y, et al.. "Assessment of non-tumor liver parenchyma damage in advanced gastric cancer treatment with transarterial infusion chemotherapy: a study using imaging and hepatic injury indicators.." Frontiers in oncology, vol. 15, 2025, pp. 1537688.
PMID
40046626 ↗
Abstract 한글 요약
[INTRODUCTION] This study aimed to evaluate non-tumor liver parenchymal injury in advanced gastric cancer patients undergoing transarterial infusion chemotherapy (TAI) using imaging parameters and liver injury biomarkers, providing objective evidence for early detection of drug-induced liver injury.
[METHODS] A retrospective analysis was conducted on 52 advanced gastric cancer patients who received TAI at our center from July 2015 to July 2023. Abdominal CT images and laboratory data were collected before and after treatment. Imaging postprocessing software was used to measure the liver-to-spleen (L/S) attenuation ratio and spleen volume. Liver fibrosis indices (APRI, FIB-4) and liver function scores (Child-Pugh, ALBI) were calculated. Statistical analysis included Wilcoxon rank-sum test and paired t-test for pre- and post-treatment comparisons.
[RESULTS] Patients received an average of 2.80 TAI cycles over 8.3 weeks. Post-treatment, 76.92% (40/52) showed a significant reduction in L/S attenuation ratio (1.23 ± 0.13 vs. 1.12 ± 0.1, P < 0.01), and 73.1% (38/52) exhibited increased spleen volume (151,219.33 mm vs. 202, 171.32 mm, P < 0.01). Liver fibrosis indices significantly increased: APRI (0.19 ± 0.15 vs. 0.37 ± 0.27) and FIB-4 (1.29 ± 0.88 vs. 2.24 ± 1.38) (P < 0.01). No significant changes were observed in ALBI (-2.7 ± 0.41 vs. -2.58 ± 0.43) or Child-Pugh scores (5.31 ± 0.47 vs. 5.38 ± 0.64) (P > 0.05).
[DISCUSSION] Transarterial infusion chemotherapy for advanced gastric cancer results in short-term damage to the non-tumor liver parenchyma, with imaging findings showing hepatic steatosis (reduction in L/S ratio) and splenomegaly. Serum markers suggest progression of hepatic fibrosis, consistent with the pathological features of hepatic sinusoidal obstruction syndrome. The combination of CT imaging and APRI/FIB-4 provides a sensitive method for detecting subclinical liver injury, reflecting pathological changes earlier than traditional liver function scores.
[METHODS] A retrospective analysis was conducted on 52 advanced gastric cancer patients who received TAI at our center from July 2015 to July 2023. Abdominal CT images and laboratory data were collected before and after treatment. Imaging postprocessing software was used to measure the liver-to-spleen (L/S) attenuation ratio and spleen volume. Liver fibrosis indices (APRI, FIB-4) and liver function scores (Child-Pugh, ALBI) were calculated. Statistical analysis included Wilcoxon rank-sum test and paired t-test for pre- and post-treatment comparisons.
[RESULTS] Patients received an average of 2.80 TAI cycles over 8.3 weeks. Post-treatment, 76.92% (40/52) showed a significant reduction in L/S attenuation ratio (1.23 ± 0.13 vs. 1.12 ± 0.1, P < 0.01), and 73.1% (38/52) exhibited increased spleen volume (151,219.33 mm vs. 202, 171.32 mm, P < 0.01). Liver fibrosis indices significantly increased: APRI (0.19 ± 0.15 vs. 0.37 ± 0.27) and FIB-4 (1.29 ± 0.88 vs. 2.24 ± 1.38) (P < 0.01). No significant changes were observed in ALBI (-2.7 ± 0.41 vs. -2.58 ± 0.43) or Child-Pugh scores (5.31 ± 0.47 vs. 5.38 ± 0.64) (P > 0.05).
[DISCUSSION] Transarterial infusion chemotherapy for advanced gastric cancer results in short-term damage to the non-tumor liver parenchyma, with imaging findings showing hepatic steatosis (reduction in L/S ratio) and splenomegaly. Serum markers suggest progression of hepatic fibrosis, consistent with the pathological features of hepatic sinusoidal obstruction syndrome. The combination of CT imaging and APRI/FIB-4 provides a sensitive method for detecting subclinical liver injury, reflecting pathological changes earlier than traditional liver function scores.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Role of HOXA transcript antisense RNA myeloid-specific 1 in cancer (Review).
- Ferroptotic resistance involved in PTEN-loss prostate cancer progression.
- Analysis of the therapeutic effect of allogeneic hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia with fusion gene: a case series.
- Rat Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Promote the Proliferation, Invasion, and Metastasis and Inhibit Apoptosis of Colorectal Cancer Stem Cells.
- Evaluating the efficacy of the endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach in identifying occult lateral cervical lymph node metastasis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.
- Multifocal hepatocellular carcinoma in a noncirrhotic liver: A diagnostic pitfall mimicking cholangiocarcinoma and metastatic disease.
- Sintilimab Plus Nanoparticle Polymeric Micellar Paclitaxel and S-1 as First-Line Treatment in HER2-Negative Advanced Gastric Cancer: A Real-World Study.
- Clinical value of geriatric nutritional risk index and pan-immune-inflammation value in locally advanced gastric cancer receiving neoadjuvant chemotherapy.
- Gene-guided repurposing identifies dihydroergotamine as a candidate inhibitor of the BCL2-SIVA1 axis in advanced gastric cancer in vitro.
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.